AR101637A1 - Combinaciones de gabapentinoides y ligandos de receptores sigma - Google Patents
Combinaciones de gabapentinoides y ligandos de receptores sigmaInfo
- Publication number
- AR101637A1 AR101637A1 ARP140104701A ARP140104701A AR101637A1 AR 101637 A1 AR101637 A1 AR 101637A1 AR P140104701 A ARP140104701 A AR P140104701A AR P140104701 A ARP140104701 A AR P140104701A AR 101637 A1 AR101637 A1 AR 101637A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- aromatic
- nr8r9
- heterocyclyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 108010085082 sigma receptors Proteins 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 17
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 239000011885 synergistic combination Substances 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 208000002193 Pain Diseases 0.000 abstract 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- -1 ethyl hydrochloride Chemical compound 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382517 | 2013-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101637A1 true AR101637A1 (es) | 2017-01-04 |
Family
ID=49876521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104701A AR101637A1 (es) | 2013-12-17 | 2014-12-17 | Combinaciones de gabapentinoides y ligandos de receptores sigma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160310501A1 (https=) |
| EP (1) | EP3082790A1 (https=) |
| JP (1) | JP2017503765A (https=) |
| KR (1) | KR20160098426A (https=) |
| CN (1) | CN105873580B (https=) |
| AR (1) | AR101637A1 (https=) |
| AU (1) | AU2014364644A1 (https=) |
| CA (1) | CA2933057A1 (https=) |
| IL (1) | IL245977A0 (https=) |
| MA (1) | MA39146A1 (https=) |
| MX (1) | MX2016007286A (https=) |
| PH (1) | PH12016501095A1 (https=) |
| SG (1) | SG11201604478UA (https=) |
| TN (1) | TN2016000229A1 (https=) |
| TW (1) | TW201607539A (https=) |
| WO (1) | WO2015091505A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| TW201607538A (zh) | 2013-12-17 | 2016-03-01 | 以斯提夫博士實驗室股份有限公司 | 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物 |
| JP2021508331A (ja) * | 2017-12-19 | 2021-03-04 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 眼投与のためのｗ／ｏ／ｗマイクロエマルジョン |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN120437109B (zh) * | 2025-07-09 | 2025-09-26 | 湖南一格制药有限公司 | 一种稳定性优异的苯磺酸美洛加巴林制剂组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| JP3856816B2 (ja) | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体 |
| ATE323067T1 (de) | 1997-10-27 | 2006-04-15 | Warner Lambert Co | Zyklische aminosäuren und deren derivate als arzneimittel |
| CN1131855C (zh) | 1997-12-16 | 2003-12-24 | 沃尼尔·朗伯公司 | 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
| CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| SI1045839T1 (en) | 1997-12-16 | 2004-06-30 | Warner-Lambert Company Llc | Novel amines as pharmaceutical agents |
| WO1999061424A1 (en) | 1998-05-26 | 1999-12-02 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| US6166072A (en) | 1998-08-03 | 2000-12-26 | Allelix Neuroscience, Inc. | Amino acid derivatives |
| US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
| US6451857B1 (en) * | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| ES2228524T3 (es) | 1999-05-26 | 2005-04-16 | Warner-Lambert Company Llc | Aminoacidos policiclicos fundidos utilizados como agentes farmaceuticos. |
| PT1185524E (pt) | 1999-05-28 | 2005-04-29 | Warner Lambert Co | Analogos de gaba substituidos por 3-heteroarilalquilo |
| PT1187832E (pt) | 1999-06-02 | 2003-03-31 | Warner Lambert Co | Amino heterociclos uteis como agentes farmaceuticos |
| SK12822003A3 (sk) | 2001-04-19 | 2004-04-06 | Warner - Lambert Company Llc | Fúzne bicyklické alebo tricyklické aminokyseliny |
| CA2576144C (en) * | 2004-08-27 | 2012-12-11 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| EP1820502A1 (en) * | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2292236A1 (en) | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| EP2335688A1 (en) | 2009-11-25 | 2011-06-22 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions comprising sigma receptor ligands |
| BR112012012456A2 (pt) | 2009-11-25 | 2020-08-11 | Laboratorios Del Dr. Esteve, S.A. | sal de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina,processo para a preparação do sal de cloridrato, composição farmacêutica e sal de cloridrato |
| EP2353591A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| SG10201500832PA (en) | 2010-02-04 | 2015-04-29 | Esteve Labor Dr | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) * | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2460519A1 (en) | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
| EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2818166A1 (en) * | 2013-06-26 | 2014-12-31 | Laboratorios del Dr. Esteve S.A. | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
-
2014
- 2014-12-16 WO PCT/EP2014/077992 patent/WO2015091505A1/en not_active Ceased
- 2014-12-16 CA CA2933057A patent/CA2933057A1/en not_active Abandoned
- 2014-12-16 US US15/104,752 patent/US20160310501A1/en not_active Abandoned
- 2014-12-16 MA MA39146A patent/MA39146A1/fr unknown
- 2014-12-16 EP EP14823952.8A patent/EP3082790A1/en not_active Withdrawn
- 2014-12-16 TW TW103143904A patent/TW201607539A/zh unknown
- 2014-12-16 TN TN2016000229A patent/TN2016000229A1/en unknown
- 2014-12-16 AU AU2014364644A patent/AU2014364644A1/en not_active Abandoned
- 2014-12-16 JP JP2016536584A patent/JP2017503765A/ja not_active Ceased
- 2014-12-16 CN CN201480072218.6A patent/CN105873580B/zh not_active Expired - Fee Related
- 2014-12-16 KR KR1020167018971A patent/KR20160098426A/ko not_active Withdrawn
- 2014-12-16 MX MX2016007286A patent/MX2016007286A/es unknown
- 2014-12-16 SG SG11201604478UA patent/SG11201604478UA/en unknown
- 2014-12-17 AR ARP140104701A patent/AR101637A1/es unknown
-
2016
- 2016-06-01 IL IL245977A patent/IL245977A0/en unknown
- 2016-06-08 PH PH12016501095A patent/PH12016501095A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL245977A0 (en) | 2016-07-31 |
| WO2015091505A1 (en) | 2015-06-25 |
| KR20160098426A (ko) | 2016-08-18 |
| CN105873580B (zh) | 2020-08-25 |
| TN2016000229A1 (en) | 2017-10-06 |
| CN105873580A (zh) | 2016-08-17 |
| EP3082790A1 (en) | 2016-10-26 |
| MX2016007286A (es) | 2016-08-04 |
| CA2933057A1 (en) | 2015-06-25 |
| JP2017503765A (ja) | 2017-02-02 |
| PH12016501095A1 (en) | 2016-07-11 |
| MA39146A1 (fr) | 2017-11-30 |
| AU2014364644A1 (en) | 2016-06-23 |
| SG11201604478UA (en) | 2016-07-28 |
| TW201607539A (zh) | 2016-03-01 |
| US20160310501A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101637A1 (es) | Combinaciones de gabapentinoides y ligandos de receptores sigma | |
| AR101638A1 (es) | Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma | |
| AR096709A1 (es) | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
| AR084730A1 (es) | Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| AR100021A1 (es) | Combinaciones de ligando de receptores sigma y aine | |
| AR107694A1 (es) | Heteroarilos inhibidores de pad4 | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
| SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| TN2014000436A1 (en) | Inhibitors of platelet aggregation | |
| AR082441A1 (es) | Uso de ligandos sigma en la hiperalgesia inducida por opioides | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR086632A1 (es) | Ligandos sigma para la prevencion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CO6410301A2 (es) | 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |